BioSpace News Archive

CymaBay Therapeutics, Inc. announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022.

ProSomnus, Inc., the pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea, will report its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023.

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022.

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”) today announced it has submitted an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”), requesting approval to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from alcohol use disorder (“AUD”).

Shattuck Labs, Inc. today announced preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from the company’s GADLEN platform.

Inhibikase Therapeutics, Inc. today announced that it will host a virtual R&D Event on Wednesday, March 22, 2023 at 11:00 am ET.

Neogen Corporation (NASDAQ: NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, March 30, 2023.

The Lung Cancer Research Foundation (LCRF) today announced a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer.

Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) (“Cloud DX” or the “Corporation”) is pleased to announce the closing of the first tranche of the private placement (the “Private Placement”) of units of the Corporation (the “Units”) for aggregate gross proceeds of $2,601,884. The Corporation expects to close the second and final tranche of the Private Placement on or before March 31, 2023.

Oculis Holding AG (Nasdaq: OCS) (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the completion of enrollment for its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01.